Spatially Resolved Multiomics Reveals Metabolic Remodeling and Autophagy Activation in Adamantinomatous Craniopharyngiomas
- PMID: 41489092
- DOI: 10.1002/advs.202516965
Spatially Resolved Multiomics Reveals Metabolic Remodeling and Autophagy Activation in Adamantinomatous Craniopharyngiomas
Abstract
Adamantinomatous craniopharyngioma (ACP), a benign yet highly recurrent and therapy-resistant intracranial tumor, remains a considerable clinical challenge because of its complex pathological structure, infiltrative growth, and limited treatment options. Here, integrated spatially resolved multiomics is employed-including single-cell spatial transcriptomics via CosMx SMI and spatially resolved metabolomics via AFADESI-MSI, accompanied by bulk metabolomics and functional validation-to unravel the driving factors of ACP progression and recurrence. Analysis results reveal three interdependent biological hallmarks: first, the spatial segregation and molecular heterogeneity of 10 distinct tumor epithelial cell subpopulations within the ACP, each of which presents unique transcriptional signatures; second, in tumor regions and recurrent tumor epithelium tissues, stronger transporter-mediated choline/ethanolamine uptake from cystic fluid and significant upregulation of phosphatidylcholine (PC) and phosphatidylethanolamine (PE) synthesis is observed, creating the enhanced "cystic fluid-tumor cell" and "choline/ethanolamine-PC/PE" metabolic axis, and demonstrating the spatial metabolic remodeling of ACP; and third, this metabolic axis directly couples to autophagy activation of corresponding regions in ACP tissue, which is validated by multi-immunohistochemistry for Beclin1 and GABARAP. Together, these findings reveal metabolic remodeling and autophagic activation as critical drivers of ACP progression and recurrence and provide an opportunity for precise biomarker-driven treatment of this intractable tumor.
Keywords: adamantinomatous craniopharyngioma; glycerophospholipid metabolism; multiomics; single‐cell spatial transcriptomics; spatially resolved metabolomics.
© 2026 The Author(s). Advanced Science published by Wiley‐VCH GmbH.
References
-
- H. L. Müller, T. E. Merchant, M. Warmuth‐Metz, J.‐P. Martinez‐Barbera, and S. Puget, “Craniopharyngioma,” Nature Reviews Disease Primers 5 (2019): 75.
-
- W. An, S. Li, Y. An, and Z. Lin, “Molecular Subtypes of Adamantinomatous Craniopharyngiomas,” Neuro‐Oncology 27 (2025): 1180–1192.
-
- C. Gaston‐Massuet, C. L. Andoniadou, M. Signore, et al., “Increased Wingless (Wnt) Signaling in Pituitary Progenitor/Stem Cells Gives Rise to Pituitary Tumors in Mice and Humans,” Proceedings of the National Academy of Sciences 108 (2011): 11482–11487.
-
- D. N. Louis, A. Perry, P. Wesseling, et al., “The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary,” Neuro‐Oncology 23 (2021): 1231–1251.
-
- F. Henderson and T. H. Schwartz, “Update on Management of Craniopharyngiomas,” Journal of Neuro‐Oncology 156 (2022): 97–108.